Loratadine Sales Keep Perrigo On Track To Meet Core Business Growth Goals
This article was originally published in The Tan Sheet
Executive Summary
Perrigo expects to meet its fiscal 2004 target for core business growth despite continued delays in the approval of its 10 mg loratadine tablets (Schering-Plough's Claritin)
You may also be interested in...
Leiner Looks To Rule Claritin Equivalent Market With Summer Launches
Leiner Health Products will seek to control the store brand loratadine market with late summer launches of equivalents to Schering-Plough's Claritin RediTabs and D-24
Perrigo’s Generic Loratadine Offerings Could Boost Firm’s Cough/Cold Sales
Perrigo's planned introduction of two generic loratadine formulations in early 2004 is expected to improve the firm's lackluster cough/cold sales in the second half of its fiscal year
Perrigo Nets Former Pharmacia Counsel Kingma To Support New Strategy
Perrigo's appointment of former Pharmacia associate general counsel Todd Kingma to VP and general counsel reflects the firm's recent expansion into generic Rx pharmaceuticals and bolsters its OTC patent defense team